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Key messages
What is already known about this subject?
 ► The SLE Disease Activity Index (SLEDAI) is the 
most widely used SLE disease activity measure 
and the core determinant in the SLE Responder 
Index (SRI) applied as primary endpoint in 
clinical trials.
 ► The performance of SLEDAI in detecting 
clinically meaningful changes in disease activity 
is limited.
What does this study add?
 ► This study presents the derivation and 
validation of the SLE Disease Activity Score 
(SLE-DAS), a new continuous global score to 
assess disease activity in SLE. The SLE-DAS 
provides a more accurate identification of 
clinically meaningful changes over time, with 
a much higher sensitivity as compared with 
SLEDAI-2K and similar specificity. The SLE-DAS 
presented higher performance in predicting 
damage accrual, as compared to SLEDAI-2K.
How might this impact on clinical practice or 
future developements?
 ► The use of the SLE-DAS in clinical practice and 
as an outcome in clinical trials will allow a 
much higher discriminative power to detect 
clinically meaningful changes in SLE disease 
activity. Importantly for its use, collection of 
SLE-DAS items requires a clinical workup time 
similar to SLEDAI, and much lower than the 
British Isles Lupus Assessment Group and SRI.
AbSTrACT
Objectives To derive and validate a new disease 
activity measure for systemic lupus erythematosus (sle), 
the sle Disease activity score (sle-Das), with improved 
sensitivity to change as compared with sle Disease 
activity index (sleDai), while maintaining high specificity 
and easiness of use.
Methods We studied 520 patients with sle from two 
tertiary care centres (derivation and validation cohorts). 
at each visit, disease activity was scored using the 
Physician Global assessment (PGa) and sleDai 2000 
(sleDai-2K). To construct the sle-Das, we applied 
multivariate linear regression analysis in the derivation 
cohort, with PGa as dependent variable. The formula was 
validated in a different cohort through the study of: (1) 
correlations between sle-Das, PGa and sleDai-2K; (2) 
performance of sleDai-2K and sle-Das in identifying 
a clinically meaningful change in disease activity 
(ΔPGa≥0.3); and (3) accuracy of sleDai-2K and sle-
Das time-adjusted means in predicting damage accrual.
results The final sle-Das instrument included 17 
items. sle-Das was highly correlated with PGa (r=0.875, 
p<0.0005) and sleDai-2K (r=0.943, p<0.0005) in the 
validation cohort. The optimal discriminative Δsle-
Das cut-off to detect a clinically meaningful change 
was 1.72. in the validation cohort, sle-Das showed 
a higher sensitivity than sleDai-2K (change ≥4) to 
detect a clinically meaningful improvement (89.5% 
vs 47.4%, p=0.008) or worsening (95.5% vs 59.1%, 
p=0.008), while maintaining similar specificities. sle-
Das performed better in predicting damage accrual than 
sleDai-2K.
Conclusion sle-Das has a good construct validity and 
has better performance than sleDai-2K in identifying 
clinically significant changes in disease activity and in 
predicting damage accrual.
InTrOduCTIOn
The accurate assessment of disease activity in 
patients with systemic lupus erythematosus (SLE) 
is a critical tool for clinical practice, observational 
studies and clinical trials.1 2 Over the last three 
decades, multiple disease activity indices have been 
developed. Yet, all these instruments have important 
limitations, hindering their usefulness.3 Hence, the 
standardised measurement of SLE disease activity 
remains a challenging task.4 5
The SLE Disease Activity Index (SLEDAI), which 
includes the SLEDAI 2000 (SLEDAI-2K) and Safety 
of Estrogens in Lupus Erythematosus National 
Assessment (SELENA)-SLEDAI versions, is the 
most widely used SLE disease activity measure.6–8 
Furthermore, SLEDAI is the core determinant in the 
SLE Responder Index 4 used as primary endpoint 
in recent clinical trials.9–13 However, the perfor-
mance of SLEDAI in detecting clinically meaningful 
changes in disease activity is limited, since each 
item of SLEDAI is scored dichotomically, with the 
same numerical weight regardless of the severity 
of change observed. Only remission of any lupus 
feature, but not partial improvement, is captured 
as a change in SLEDAI score; likewise, an increased 
severity of any previously active manifestation 
cannot be scored. In addition, potentially severe 
lupus manifestations, such as haemolytic anaemia, 
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Table 1 Clinical and laboratory parameters attributable to systemic lupus erythematosus (SLE), assessed at each outpatient visit
Manifestation description
1. Arthritis Number of swollen joints in 28-joint count.
2. Localized skin rash Acute, subacute and chronic cutaneous lupus rashes included in the SLICC classification criteria, only above the neck.
3. Generalized skin rash Acute, subacute and chronic cutaneous lupus rashes included in the SLICC classification criteria, above and below the neck.
4. Alopecia Abnormal, patchy or diffuse loss of hair.
5. Mucosal ulcers Oral or nasal ulcerations.
6. Systemic vasculitis Systemic vasculitis involving large and medium-sized vessels and lupus enteritis.
7. Mucocutaneous vasculitis Any mucocutaneous vasculitis and chilblain lupus.
8. Neuropsychiatric involvement Neuropsychiatric features included in the SLICC classification criteria for SLE, including recent onset of seizure, psychosis, organic brain 
syndrome, acute confusional state, SLE retinal changes, peripheral neuropathy, myelopathy, lupus headache, cerebrovascular accident and 
aseptic meningitis.
9. Cardiac/pulmonary involvement Including shrinking lung, interstitial pneumonitis, diffuse alveolar haemorrhage, pulmonary hypertension, myocarditis, valvular dysfunction, 
Libman-Sacks endocarditis.
10.Serositis Including sterile peritonitis in addition to pleurisy and pericarditis.
11.Myositis Proximal muscle aching/weakness with elevated CK/aldolase or electromyogram changes or a biopsy showing myositis.
12.Proteinuria Urinary protein-creatinine ratio (mg/g) or 24 hours urinary protein (mg/24 hours), above 500 mg/g and 500 mg/24 hours, respectively.
13.Hypocomplementaemia Decrease in C3 or C4 below the lower limit of normal for testing laboratory.
14.Increased anti-dsDNA Increase in DNA binding above the upper limit of normal for testing laboratory.
15.Thrombocytopenia Platelet count (10^9/L), below 100x10^9/L platelets.
16.Leucopenia Leucocyte count (10^9/L), below 3x10^9/L white blood cells.
17. Haemolytic anaemia Anaemia with positive direct Coombs test, increased serum LDH and low serum haptoglobin.
CK, creatine kinase; LDH, lactic dehydrogenase; SLICC, Systemic Lupus International Collaborating Clinics.
pneumonitis or gastrointestinal involvement, are not scored in 
SLEDAI.
These limitations have important implications on target-driven 
management of SLE in daily clinical practice, and in assessing the 
efficacy of new medications in clinical trials. In fact, despite many 
promising lupus treatments reaching early-phase human studies 
during last decades, none except belimumab has yet demon-
strated efficacy in phase III trials using these outcome measures, 
in contrast with the clinician’s impression of efficacy.14–19 Thus, 
there is an unmet need for tools able to accurately capture clini-
cally meaningful changes in SLE disease activity.
Herein, we describe the development and validation of a new 
instrument for the measurement of SLE disease activity: the 
SLE Disease Activity Score (SLE-DAS).20 The aim of SLE-DAS 
is to provide an accurate, continuous and user-friendly global 
measure of SLE disease activity with improved sensitivity to 
change and high specificity, in comparison to SLEDAI-2K.
PATIenTS And MeTHOdS
Study and settings
Longitudinal cohort study conducted at CHUC Lupus Clinic 
at Rheumatology Department, Centro Hospitalar e Univer-
sitário de Coimbra (CHUC), Portugal (derivation cohort) and 
at Rheumatology Unit, University of Padova, Italy (validation 
cohort). This project adheres to the principles of the Declaration 
of Helsinki and was approved by the local ethics committees. 
Informed consent was obtained from all patients.
Patients
Consecutive patients with SLE fulfilling American College of 
Rheumatology (ACR’97) and/or Systemic Lupus International 
Collaborating Clinics (SLICC’12) classification criteria, enrolled 
in the CHUC Lupus Cohort from January 2014 to December 
2017 and in the Padova Lupus Cohort, from January 2013 
to June 2018, were studied.21 22 Data from the CHUC Lupus 
Cohort were used for derivation and internal validation of the 
SLE-DAS and data from the Padova Lupus Cohort were used for 
external validation.
Parameters assessed
Clinical and laboratory assessment considered all manifesta-
tions included in SLEDAI-2K and in the current definitions of 
low disease activity (LDA) or remission, in a total of 17 vari-
ables (table 1).8 12 13 Disease activity in the previous 30 days was 
scored, by one senior rheumatologist with large experience in 
SLE management in each cohort, using Physician Global Assess-
ment (PGA) (0–3) and SLEDAI-2K (0–105).8 Organ damage was 
evaluated at each outpatient visit using the SLICC/ACR Damage 
Index for SLE (SDI).23
Moreover, in the Padova Lupus Cohort, the disease activity 
data at the last follow-up visit were compared with the previous 
one and the change was classified by the senior physician as 
reflecting: (1) clinically meaningful improvement; (2) no clini-
cally meaningful change; and (3) clinically meaningful worsening.
data analysis and statistics
On clinical grounds, we adopted the guiding principle that all 
variables listed in table 1 ought to be included in the final instru-
ment, given that their relevance is well established in practice.
derivation of the disease activity score
For derivation of the SLE-DAS, data from the CHUC Lupus 
Cohort were used. Data from the visit with the highest disease 
activity during follow-up from each patient were selected for 
analysis.
Multivariate linear regression was applied, with PGA as depen-
dent variable. All disease manifestations included in table 1 were 
considered as potential independent variables for the model. 
Because the precision of an estimated coefficient may be affected 
if the corresponding variable has little sample variation, and the 
regression model ability to predict future observations can be 
compromised increasing the number of variables, only variables 
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Table 2 Baseline characteristics of the patients included (n=520)
derivation cohort
(n=324)
Validation cohort
(n=196)
Female gender, n (%) 282 (87) 177 (85.2)
Caucasian, n (%) 317 (97.8) 185 (94.4)
Age, mean±SD (years) 44.5±0.8 44.6±0.9
Disease duration, mean±SD (years) 10.8±0.5 15.4±0.7
PGA, median (range) 0.2 (0–2.5) 0.2 (0–2.0)
SLEDAI-2K, median (range) 4 (0–26) 2 (0–22)
PGA: Physician Global Assessment; SLEDAI-2K, Systemic Lupus Erythematosus 
Disease Activity Index 2000.
Figure 1 The final formula of Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS). Alopecia, presence of alopecia (1=Yes, 0=No); 
Arthitis, presence of arthritis (1=Yes, 0=No); CardioPulm, presence of cardiac/pulmonary involvement (1=Yes, 0=No); GeneralRash, presence of 
generalized cutaneous rash (1=Yes, 0=No); Haemolytic, presence of haemolytic anaemia (1=Yes, 0=No); HypoC, presence of hypocomplementaemia 
(1=Yes, 0=No); IncreasedAnti-dsDNA, increased anti-dsDNA levels (1=Yes, 0=No); Leuc, leucopenia <3x10^9/L (1=Yes, 0=No); LeucCount, 
leucocyte count (10^9/L); LocalRash, presence of localized cutaneous rash (1=Yes, 0=No); MucocutVasculitis, presence of mucocutaneous vasculitis 
(1=Yes, 0=No); MucosalUlcers, presence of mucosal ulcers (1=Yes, 0=No); Myositis, presence of myositis (1=Yes, 0=No); Neuropsych, presence 
of neuropsychiatric involvement (1=Yes, 0=No); PlatCount, platelet count (10^9/L); PProt, proteinuria >500 mg/24 hours (1=Yes, 0=No); Prot, 
proteinuria (mg/24 hours); Serositis, presence of serositis (1=Yes, 0=No); SJC, swollen joint count (0–28); SystemicVasc, presence of systemic vasculitis 
(1=Yes, 0=No); Thromb, thrombocytopenia <100x10^9/L (1=Yes, 0=No).
with more than 10 observations were included in the multivar-
iate linear regression model. The remaining manifestations were 
attributed a discretionary weight score by the senior investigator 
(LSI), taking into account the coefficients of the other variables 
in the regression model and also the relative impact of these vari-
ables in the expert physician’s disease activity assessment.
Several different functions of disease manifestations were 
sequentially tested in looking for the model with the best possible 
adjustment to PGA. Urinary protein excretion, platelet and white 
cell counts were modelled considering their non-linear impact 
on disease activity assessment as reflected in PGA. Regarding 
arthritis, two variables were included in the model: a dummy 
variable indicating the presence or absence of arthritis, and the 
number of swollen joints, in order to improve the assessment of 
severity.
Internal validation
The construct validity was assessed by comparing the global 
score of the SLE-DAS with PGA and SLEDAI-2K, using Spear-
man’s correlation coefficients , at the last follow-up visit. During 
follow-up, the ability of SLE-DAS to discriminate a clinically 
meaningful worsening or improvement in SLE disease activity 
(defined as a change in PGA≥0.3) was assessed using receiver 
operating characteristic (ROC) analysis and compared with the 
performance of SLEDAI-2K. The areas under the ROC curves 
(AUC) were used to evaluate and compare the discriminative 
ability of SLE-DAS and SLEDAI-2K. By analyses of ROC curves, 
ideal cut-off values of ΔSLE-DAS to detect clinically meaningful 
worsening/improvement were identified, and its sensitivity, spec-
ificity, and positive and negative predictive values (PPV, NPV) 
were determined. McNemar’s test was used to assess whether 
there was a significant difference between the SLE-DAS and 
SLEDAI-2K sensitivity and specificity for clinically meaningful 
changes.
external validation
The external validation was performed using data from patients 
enrolled in the Padova Lupus Cohort. Construct validity was 
assessed through Spearman’s correlation between SLE-DAS, 
SLEDAI-2K and PGA at last follow-up visit. Considering the last 
two assessments in the follow-up period, patients with clinically 
meaningful worsening or improvement were identified. ROC 
curves were used to evaluate the performance of SLE-DAS and 
SLEDAI-2K in detecting clinically meaningful changes. McNe-
mar’s test was used to assess whether there was a significant 
difference between the SLE-DAS and SLEDAI-2K sensitivity and 
specificity for clinically meaningful changes.
Patients with more than two follow-up visits and regular 
follow-up (defined as less than 12 months between visits) were 
included in the analysis of the ability of adjusted mean of SLE-DAS 
(amSLE-DAS) and adjusted mean of SLEDAI-2K (amSLEDAI) to 
predict damage accrual. The amSLE-DAS and amSLEDAI were 
determined for each patient and each visit as the area under the 
curve (AUC) of the SLE-DAS and SLEDAI-2K values over time, 
divided by the total length of the time period until that visit.24 
Cox regression with time-dependent covariates25 was applied to 
assess the ability of the amSLE-DAS and amSLEDAI to predict 
damage accrual (ΔSDI≥1 during follow-up). The impact of each 
one of these variables in the hazard of damage was measured 
adjusting for other damage risk factors.26 Two models were 
estimated, one with amSLE-DAS (model 1) and another with 
amSLEDAI (model 2). The amSLE-DAS and amSLEDAI models 
were compared using Akaike information criterion (AIC) and 
Bayesian information criterion (BIC). The likelihood ratio test 
was applied to evaluate the importance of amSLE-DAS in a 
model which already has the information given by amSLEDAI 
and vice versa. Non-rejection of the null hypothesis indicates 
that the variables not included in the reduced model do not 
contribute significantly to predict the outcome.
IBM SPSS Statistics, V.24, and R software, V.3.1.2 were used, 
and p<0.05 was considered statistically significant.27
reSulTS
Characteristics of the patients included
A total of 520 patients with SLE were included: 324 in the deri-
vation cohort and 196 in the external validation cohort. Baseline 
characteristics of the patients included are presented in table 2.  o
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Figure 2 Receiver operating characteristic (ROC) curves comparing the performance of Systemic Lupus Erythematosus Disease Activity Score (SLE-
DAS) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) to detect a clinically meaningful improvement (A, C) and worsening 
(B, D) in SLE disease activity. A and B correspond to the ROC curves of the derivation cohort and C and D correspond to the ROC curves of the external 
validation cohort.
determination of item weights and derivation of the Sle-dAS
Swollen joints, high urinary protein excretion, low platelet 
count, low white cell count, localized and generalized lupus 
rash, alopecia, mucosal membrane lesions, mucocutaneous 
vasculitis, low complement and increased levels of anti-dsDNA 
were observed in more than 10 patients and were included in the 
multivariate linear regression model. Urinary protein excretion, 
platelet count and white blood cell count were best modelled 
using the natural logarithmic function. These clinical and labo-
ratory features were significantly associated with disease activity 
(as defined by PGA) in the multivariate model, and the R2 of the 
model was 0.91.
The remaining variables, neuropsychiatric involvement, 
systemic vasculitis, cardiac/pulmonary involvement, myositis, 
serositis and haemolytic anaemia were attributed discretionary 
weights, by expert decision as described above. These weights 
were incorporated into the final model.
The final SLE-DAS instrument is the sum of all the 17 weighted 
items (figure 1). The weighted scores of all these items and the 
detailed definition of each one can be found in the online supple-
mentary table S1 and online supplementary table S2, respectively.
Internal validation of Sle-dAS
In the derivation cohort, SLE-DAS score was highly correlated 
with PGA, as expected (rs=0.975, p<0.0005), and with 
SLEDAI-2K (rs=0.94, p<0.0005) at the last follow-up visit. 
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Table 3 Performance of SLE-DAS and SLEDAI-2K to detect clinically significant change in SLE disease activity
ΔSle-dAS≥1.72 ΔSledAI-2K≥4
Sens Spec PPV nPV Sens Spec PPV nPV
Derivation cohort
  Clinically meaningful improvement 82.1 96.9 87.3 95.4 44.8 96.5 76.9 87.0
  Clinically meaningful worsening 93.1 97.7 90.0 98.5 46.6 99.6 96.4 89.5
Validation cohort
  Clinically meaningful improvement 89.5 100 100 98.9 47.4 99.4 90 94.5
  Clinically meaningful worsening 95.5 98.2 87.5 99.4 59.1 99.4 92.9 94.9
SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000; SLE-DAS, SLE Disease Activity Score.
NPV, negative predictive value (%); PPV: positive predictive value (%); SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000; SLE-DAS, SLE Disease 
Activity Score; Sens, sensitivity (%); Spec, specificity (%).
Table 4 Multivariate Cox regression analysis for damage accrual in the validation cohort
Factors
Model 1 Model 2
Hr (95% CI) P value Hr (95% CI) P value
Gender (female) 0.606 (0.277 to 1.326) 0.2099 0.500 (0.236 to 1.059) 0.0704
Disease duration (years) 1.036 (0.999 to 1.073) 0.0554 1.041 (1.004 to 1.079) 0.0297
Age at diagnosis (≤25 years) 0.690 (0.356 to 1.339) 0.2724 0.6307 (0.319 to 1.249) 0.1860
Lupus nephritis at baseline (yes) 0.653 (0.318 to 1.340) 0.2452 0.874 (0.438 to 1.742) 0.7017
Prednisolone at baseline (mg/day) 1.047 (0.990 to 1.106) 0.1097 1.078 (1.021 to 1.138) 0.0066
Immunosuppressants at baseline (yes) 1.057 (0.530 to 2.112) 0.8748 1.084 (0.5502 to 2.135) 0.8160
amSLE-DAS (score) 1.234 (1.134 to 1.320) <0.0005
amSLEDAI (score) 1.243 (1.131 to 1.365) <0.0005
Model 1: model with amSLE-DAS as time-dependent covariate. Model 2: model with amSLEDAI as time-dependent covariate.
amSLEDAI, adjusted mean of SLEDAI-2K (time-dependent covariate); amSLE-DAS, adjusted mean of SLE-DAS (time-dependent covariate).
Furthermore, SLEDAI-2K was also strongly correlated with PGA 
(rs=0.973, p<0.0005).
The performance of SLEDAI-2K and SLE-DAS to discriminate 
a clinically meaningful improvement or worsening (both defined 
as ΔPGA≥0.3) was assessed by ROC analysis. SLE-DAS variation 
had a higher discriminative performance (AUC=0.927 (95% 
CI 0.885 to 0.969, p<0.0005) than SLEDAI-2K (AUC=0.787 
(95% CI 0.718 to 0.857), p<0.0005) to detect a clinically 
meaningful improvement (figure 2). Variations in SLE-DAS also 
presented higher discriminative ability than SLEDAI-2K to detect 
a clinically meaningful worsening, with AUCs of 0.994 (95% CI 
0.988 to 1.000, p<0.0005) and 0.914 (95% CI 0.87 to 0.959, 
p<0.0005), respectively (figure 2). A cut-off value of 1.72 points 
in the ΔSLE-DAS was identified as the optimal discriminant for 
either a PGA increase (worsening) or decrease (improvement).
A variation in SLE-DAS≥1.72 had a higher sensitivity to 
detect a clinically meaningful change in SLE disease activity 
compared with a SLEDAI-2K≥4 variation: for improvement 
(82.1% vs 44.8%, p<0.0005) and for worsening (93.1% vs 
46.6%, p<0.0005), with similar specificities (96%–100%). Esti-
mated sensitivities, specificities, PPV and NPV using cut-offs of 
decrease and increase in SLE-DAS≥1.72 and SLEDAI-2K≥4 
points are shown in table 3.
external validation of Sle-dAS
In the external validation cohort, SLE-DAS score was strongly 
correlated with PGA (rs=0.875, p<0.0005) and SLEDAI-2K 
(rs=0.943, p<0.0005) at the last follow-up visit. SLEDAI-2K 
was also correlated with PGA (rs=0.839, p<0.0005).
For a clinically meaningful improvement, in ROC analysis, a 
change in SLE-DAS had a higher performance (AUC=0.938 (95% 
CI 0.852 to 1.000), p<0.0005) than SLEDAI-2K (AUC=0.807 
(95% CI 0.681 to 0.933), p<0.0005) (figure 2). For a clinically 
meaningful worsening, changes in SLE-DAS and SLEDAI-2K had 
an AUC of 0.998 (95% CI 0.994 to 1.000, p<0.0005) and 0.928 
(95% CI 0.855 to 1.000, p<0.0005), respectively (figure 2).
A variation in SLE-DAS≥1.72 points showed a higher sensi-
tivity to detect a clinically meaningful improvement and wors-
ening in SLE disease activity than a change in SLEDAI-2K≥4 
(89.5% vs 47.4% and 95.5% vs 59.1%, respectively, p=0.008 
for both), maintaining similar specificities. Estimated sensi-
tivities, specificities, PPV and NPV using cut-offs of increase 
or decrease in SLE-DAS≥1.72 and SLEDAI-2K≥4 points are 
reported in table 3.
A total of 192 patients had at least two visits with regular 
follow-up and were included in the analysis of the predictive 
value of amSLE-DAS and amSLEDAI for damage accrual. During 
a mean follow-up of 5 years, 44 (22.9%) patients had damage 
accrual. The amSLE-DAS and amSLEDAI were identified as 
independent predictors of damage accrual in the multivariate 
Cox regression analysis (table 4).
Three multivariate Cox regression models for damage accrual 
over follow-up were estimated: model 1 with amSLE-DAS 
and model 2 with amSLEDAI, both variables being considered 
as time-dependent covariates; and model 3 with amSLE-DAS 
and amSLEDAI as time-dependent covariates. Gender, disease 
duration, age at diagnosis, presence of lupus nephritis, pred-
nisolone dose and immunosuppressants at baseline were also 
included in these models as potential confounders (table 4). Both 
amSLE-DAS and amSLEDAI are significant predictors of damage, 
but model 1 (with amSLE-DAS) presents better fit than model 
2 (with amSLEDAI), as it has lower values of AIC (377.183 vs 
385.015, respectively) and BIC (389.673 vs 397.504, respec-
tively). Furthermore, the likelihood ratio test comparing model 
1 (with amSLE-DAS) with model 3 (containing both amSLE-DAS 
and amSLEDAI) yields a p value of 0.694, which indicates 
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that there is no predictive advantage in including amSLEDAI 
when the model already considers amSLE-DAS information. 
On the contrary, the comparison of the model 3 with model 2 
(containing only amSLEDAI) leads to the rejection of the null 
hypothesis (p=0.0047), which means that the prediction of 
damage improves significantly if we include amSLE-DAS in the 
model which already has amSLEDAI. Taken together, these anal-
yses demonstrate that disease activity measured with SLE-DAS 
over time has a higher predictive value for damage accrual than 
SLEDAI-2K.
dISCuSSIOn
SLE-DAS is a continuous global score of disease activity in SLE, 
designed to more accurately measure disease activity of SLE 
and to better assess its changes over time. SLE-DAS presented 
a good construct validity, with very high correlations with both 
SLEDAI-2K, a validated instrument, and PGA, both in the deri-
vation and in the validation cohorts. Criterion validity was 
demonstrated by the predictive value of SLE-DAS for damage 
accrual, which was better than that of SLEDAI-2K.
SLE-DAS performs much better than SLEDAI-2K in terms 
of sensitivity to detect a clinically meaningful change, while 
presenting a high specificity. Such a performance can have major 
implications in the interpretation of clinical trials applying the 
disease activity as the primary endpoint, and in daily clinical 
practice, where SLE-DAS could provide robust guidance for 
treatment in the individual patient.
The assessment of disease activity in SLE is a very challenging 
task due to the heterogeneity of the disease manifestations and 
the difficulty of incorporating in a single instrument all the poten-
tially relevant variables and their relative weights in assessing 
severity.28 Using a purely dichotomous approach to score vari-
ables, without grading the intensity of their change, makes the 
currently available tools insensitive to relevant changes, both at 
individual and group levels.29 These limitations underlie the diffi-
culties that the scientific community has faced in establishing a 
defined clinical response as the outcome measure in randomised 
controlled trials or in defining remission and LDA as the targets 
in treat-to-target strategies.28 30 Actually, the current instruments 
cannot separate remission from LDA as we do with DAS28 in 
rheumatoid arthritis.31 These observations led us to the concept 
that a continuous measure of disease activity was indispensable 
to appropriately value change and to define cut-offs for remis-
sion, LDA and moderate or high disease activity.
In the absence of a validated gold standard, we considered 
that measuring SLE activity should consider all variables that 
have deserved acceptance by the scientific community so far and 
should be modelled on experienced physicians, whose judge-
ment is validated by high-quality health outcomes documented 
in their patient cohorts.26 31 We started by acknowledging that 
in clinical practice the judgement of disease activity in a patient 
with SLE is based on a combination of laboratory and clinical 
features as well as the physician overall impression of the patient 
status (scored in PGA).28 The derivation of the SLE-DAS was 
modelled on the PGA and hence it was of utmost importance to 
ensure the accuracy of an expert clinician. Its construct validity 
was demonstrated in an external cohort with the PGA scored 
by a different expert clinician from another country and, most 
importantly, SLE-DAS was a better predictor of damage accrual 
than SLEDAI-2K, which argues for the objectivity of a better 
SLE-DAS performance.
In the SLE-DAS, the four parameters scored as continuous vari-
ables (arthritis, proteinuria, leucopenia and thrombocytopenia) 
are major drivers of its increased sensitivity to change. In addi-
tion, we expect that our new scoring algorithm and item redef-
inition, reduced from 24 (in SLEDAI) to 17 (in SLE-DAS), can 
also contribute to the improved performance of SLE-DAS. At 
least in some patients, it can be of major impact the inclusion 
of potentially severe features absent from SLEDAI (haemolytic 
anaemia, gastrointestinal and cardiopulmonary involvement), 
which were included in the current definitions of lupus LDA 
and remission.10 12 13 Assembling all these items into a quantita-
tive disease activity index provided us with a sensitive and stan-
dardised instrument to assess disease activity in SLE.
Limitations of our study include the use given to PGA, given 
its subjective nature. However, PGA is considered the gold stan-
dard to assess SLE disease activity and has received renewed 
interest with the recent development of the Lupus Foundation 
of America-Rapid Evaluation of Activity, an index based on the 
assessment of a PGA for each organ system.32 Furthermore, in 
the current study, PGA was scored always by the same senior 
rheumatologist over the follow-up, its validity being supported 
by a high correlation with SLEDAI-2K in both cohorts. Addition-
ally, the SLE-DAS was highly correlated with SLEDAI-2K and 
PGA in the internal and external validation cohort, supporting 
that PGA was consistently scored. Another important limita-
tion refers external validation being performed, so far, in only 
one centre and mainly in Caucasian patients. Further studies 
are needed to confirm these results in multicentric, multiethnic 
cohorts. The prospective assessment of data at each clinical visit 
with consistently scored SLEDAI-2K, PGA and SDI, the internal 
and external validation including the damage accrual prediction 
are important strengths of our study.
In conclusion, SLE-DAS has good construct validity, a much 
higher discriminative power to detect clinically meaningful 
changes in SLE disease activity and a higher performance in 
predicting damage accrual, as compared with SLEDAI-2K. 
Future work from our group will focus in defining cut-off values 
for remission, LDA, moderate or high disease activity and devel-
oping an online calculator.
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